References
- K.-L. Lim and C.-W. Zhang, "Molecular events underlying Parkinson's disease - an interwoven tapestry", Frontiers in Neurology, Vol. 4, 2013.
- C. Labbe and O. A. Ross, "Association studies of sporadic Parkinson's disease in the genomic era", Curr. Genomics, Vol. 15, pp. 2-10, 2014. https://doi.org/10.2174/1389202914666131210212745
- S. Lubbe and H. R. Morris, "Recent advances in Parkinson's disease genetics", J. Neurol., Vol. 261, pp. 259-266, 2014. https://doi.org/10.1007/s00415-013-7003-2
- I. Marin, "The Parkinson disease gene LRRK2: evolutionary and structural insights", Mol. Biol. Evol., Vol. 23, pp 2423-2433, 2006. https://doi.org/10.1093/molbev/msl114
- A. R. Esteves, R. H. Swedlow, and S. M. Cardoso, "LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis", Exp. Neurol., Vol. 261, pp. 206-216, 2014. https://doi.org/10.1016/j.expneurol.2014.05.025
- T. T. Wager, X. Hou, P. R. Verhoest, and A. Villalobos, "Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties", ACS Chem. Neurosci., Vol. 1, pp. 435-449, 2010. https://doi.org/10.1021/cn100008c
- J. L. Henderson, B. L. Kormos, M. M. Hayward, K. J. Coffman, J. Jasti, R. G. Kurumbail, T. T. Wager, P. R. Verhoest, G. S. Noell, Y. Chen, E. Needle, Z. Berger, S. J. Steyn, C. Houle, W. D. Hirst, and P. Galatsis, "Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor", J. Med. Chem., Vol. 58, pp 419-432, 2015. https://doi.org/10.1021/jm5014055
- A. Balupuri and S. J. Cho, "Exploration of the binding mode of indole derivatives as potent HIV-1 inhibitors using molecular docking simulations", J. Chosun Natural Sci., Vol. 6, pp. 138-142, 2013. https://doi.org/10.13160/ricns.2013.6.3.138
- A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "A CoMFA study of glycogen synthase kinase 3 inhibitors", J. Chosun Natural Sci., Vol. 8, pp. 40-47, 2015. https://doi.org/10.13160/ricns.2015.8.1.40
- A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "A CoMFA study of quinazoline-based anticancer agents", J. Chosun Natural Sci., Vol. 8, pp. 214-220, 2015. https://doi.org/10.13160/ricns.2015.8.3.214
- P. K. Balasubramanian, A. Balupuri, and S. J. Cho, "A CoMFA study of phenoxypyridine-based JNK3 inhibitors using various partial charge schemes", J. Chosun Natural Sci., Vol. 7, pp. 45-49, 2014. https://doi.org/10.13160/ricns.2014.7.1.45
-
P. K. Balasubramanian, A. Balupuri, and S. J. Cho, "Ligand-based CoMFA study on pyridylpyrazolopyridine derivatives as
$PKC{\theta}$ kinase inhibitors", J. Chosun Natural Sci., Vol. 7, pp. 253-259, 2014. https://doi.org/10.13160/ricns.2014.7.4.253 - SYBYLx2.1, Tripos International, 1699 South Hanley Road, St. Louis, Missouri, 63144, USA.
- R. D. Cramer, D. E. Patterson, and J. D. Bunce, "Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins", J. Am. Chem. Soc., Vol. 110, pp. 5959-5967, 1988. https://doi.org/10.1021/ja00226a005
- S. Wold, A. Ruhe, H. Wold, and W. J. Dunn, III, "The collinearity problem in linear regression. The partial least squares (PLS) approach to generalized inverses", SIAM Journal on Scientific and Statistical Computing, Vol. 5, pp 735-743, 1984. https://doi.org/10.1137/0905052
- R. D. Cramer, J. D. Bunce, D. E. Patterson, and I. E. Frank, "Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies", Quantitative Structure-Activity Relationships, Vol. 7, pp. 18-25, 1988. https://doi.org/10.1002/qsar.19880070105
Cited by
- Molecular Docking Studies of p21-Activated Kinase-1 (PAK1) Inhibitors vol.9, pp.3, 2016, https://doi.org/10.13160/ricns.2016.9.3.161
- HQSAR Study on Substituted 1H-Pyrazolo[3,4-b]pyridines Derivatives as FGFR Kinase Antagonists vol.10, pp.2, 2016, https://doi.org/10.13160/ricns.2017.10.2.85